Lexicon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexicon Pharmaceuticals (LXRX).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$5Upside to Avg. PT+195.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$8
May 11, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$2→$3
Mar 23, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$6
Mar 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$2→$2
Mar 5, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$4→$6
Sep 2, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Aug 7, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$1→$2
Jun 24, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 28, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 7, 2025	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$10→$6
Mar 7, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Mar 7, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 4, 2025	Leerink Partners	Roanna Ruiz	Downgrade	Outperform→Market Perform	$1
Mar 3, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 3, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Jan 29, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Jan 29, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Dec 23, 2024	Needham	Joseph Stringer	Maintained	Hold	—
Nov 25, 2024	Needham	Joseph Stringer	Maintained	Hold	—
Nov 22, 2024	Needham	Joseph Stringer	Maintained	Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

HC Wainwright & Co. analyst Joseph Pantginis maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $4 to $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Lexicon Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lexicon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

People Also Watch

People Also Watch

Lexicon Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lexicon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROCantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PROCitigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PROHC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PROHC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PROHC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target